Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment?
- PMID: 35695746
- PMCID: PMC10256281
- DOI: 10.1080/17474086.2022.2089110
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following H. pylori treatment?
Abstract
Introduction: The stomach is the most common site of origin for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Antibiotic eradication of Helicobacter pylori (H. pylori) is the standard first-line treatment, with response assessment being performed by histological evaluation of multiple gastric biopsies.
Areas covered: The objective of this review is to provide an update on results obtained using noninvasive methods, including magnetic resonance imaging (MRI), positron emission tomography combined with computed tomography (PET/CT), and most recently, PET/MRI for the assessment of disease extent and response to treatment in patients with gastric MALT lymphoma.
Expert opinion: While CT is the officially recommended imaging technique, few studies in small cohorts have suggested that diffusion-weighted MRI shows higher sensitivity, also relative to 18 F-FDG PET/CT, for both gastric and nongastric MALT lymphomas. A recent prospective study using PET/MRI with the novel CXCR4-targeting radiotracer 68 Ga-Pentixafor suggested that, for patients with gastric MALT lymphoma after H. pylori eradication, this imaging technique may provide excellent accuracy (97%) for assessment of residual or recurrent disease. Although recent studies on CXCR4-targeting PET and to some extent also diffusion-weighted MRI are promising, there is insufficient evidence to suggest a change in clinical practice.
Keywords: CXCR4 receptor; Extranodal marginal zone lymphoma; Helicobacter pylori; PET/MRI; gastroscopy; imaging.
Conflict of interest statement
Declaration of Interest:
ME Mayerhoefer has received speaker honoraria and research support from Siemens, and speaker honoraria from GE and Bristol Myers Squibb. M Raderer has received honoraria from Ipsen, Celgene, Novartis, Eli Lilly, Gilead, Eisai and Roche. B Kiesewetter has received honoraria from Ipsen, Eli Lilly and MSD.
Figures


Similar articles
-
CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication.Blood. 2022 Jan 13;139(2):240-244. doi: 10.1182/blood.2021013239. Blood. 2022. PMID: 34525196 Free PMC article.
-
Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI.Theranostics. 2019 May 27;9(12):3653-3658. doi: 10.7150/thno.31032. eCollection 2019. Theranostics. 2019. PMID: 31281504 Free PMC article.
-
The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach.Curr Opin Oncol. 2013 Sep;25(5):470-9. doi: 10.1097/01.cco.0000432523.24358.15. Curr Opin Oncol. 2013. PMID: 23942292 Review.
-
Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review.World J Gastroenterol. 2015 Jul 14;21(26):8014-20. doi: 10.3748/wjg.v21.i26.8014. World J Gastroenterol. 2015. PMID: 26185372 Free PMC article. Review.
-
18F-FDG uptake and its clinical relevance in primary gastric lymphoma.Hematol Oncol. 2010 Jun;28(2):57-61. doi: 10.1002/hon.905. Hematol Oncol. 2010. PMID: 19593742
Cited by
-
Clinical Management of Patients with Gastric MALT Lymphoma: A Gastroenterologist's Point of View.Cancers (Basel). 2023 Jul 27;15(15):3811. doi: 10.3390/cancers15153811. Cancers (Basel). 2023. PMID: 37568627 Free PMC article. Review.
-
Uncommon presentation of gastric mucosa-associated lymphoid tissue lymphoma in a 13-year-old girl: acute vomiting of blood as the initial symptom.Ann Med Surg (Lond). 2024 Jan 15;86(5):3001-3004. doi: 10.1097/MS9.0000000000001705. eCollection 2024 May. Ann Med Surg (Lond). 2024. PMID: 38694317 Free PMC article.
References
-
- Cook JR IP, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editor. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. Revised 4th ed. Lyon, France: IARC; 2017. p. 259–262.
-
- Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer. 2004. Aug;4(8):644–53. - PubMed
-
- Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011. Jun;60(6):747–58. - PubMed
-
- Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰. Annals of Oncology. 2020 2020/January/01/;31(1):17–29. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources